BMY BRISTOL MYERS SQUIBB CO — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$60.93

Period return

+5.99 (+10.90%)

Volume

7.7M

2026-07-21O $60.08 H $61.01 L $59.8 C $60.93MA5 $60.21MA20 $57.96MA60 $57.24MA120 $58.31

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 30.Highin 9 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.06%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.60%
2026. 04. 10.LowBUY3 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2026. 04. 08.LowBUY3 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 04. 08.LowHOLD3 months ago
Cantor Fitzgerald: Neutral
US analyst rating / recommendation change.
2026. 03. 18.LowHOLD4 months ago
HSBC: Hold
US analyst rating / recommendation change.
2026. 02. 25.Medium5 months ago
RBC Capital: r Perform
US analyst rating / recommendation change.
2026. 02. 23.LowBUY5 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 02. 20.MediumBUY5 months ago
Barclays: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $62.96 · 25 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 30.	After market close (AMC)	$1.61	—	—	$11.72B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$1.2	—	—	$11.2B	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-4.45	—	—	$35.96B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-5.05	—	—	$24.07B	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	11,535,106	$699.6M	0.60%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	4,662,042	$251.47M	0.39%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	3,004,111	$162.04M	0.27%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	531,198	$32.22M	0.06%	—	New position

BRISTOL MYERS SQUIBB CO브리스톨마이어스스큅

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 04. 10.	B of A Securities	—	Maintain	Buy → Buy	—	B of A Securities: Buy
2026. 04. 08.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 04. 08.	Cantor Fitzgerald	—	Maintain	Neutral → Neutral	—	Cantor Fitzgerald: Neutral
2026. 03. 18.	HSBC	—	Maintain	Hold → Hold	—	HSBC: Hold
2026. 02. 25.	RBC Capital	—	Initiate coverage	— → Sector Perform	—	RBC Capital: Sector Perform
2026. 02. 23.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight